GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
    • Scientific Advisory Board
    • Reports
      • GHTM
  • Research
    • Cross-cutting issues
      • Antimicrobial Resistance and Drug Discovery
      • Host–Pathogen Interactions
      • Genomic Surveillance and Population Mobility
      • Implementation and Translational Research
      • Information for Health Development
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • PRIME – Pathogen resistance, infection and molecular epidemiology
      • VBD – Vector borne diseases
      • CTM – Clinical tropical medicine
    • Research in numbers
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
    • BIOHUB & Available Software
    • BIOTROP Biobank
    • VIASEF & Insectaries
  • Networks & Partnerships
Home / News / GHTM’s scientific coordinator receives Pfizer Award 2015

GHTM’s scientific coordinator receives Pfizer Award 2015

December 15, 2015

Pfizer Award 2015 logo

A study by Instituto Gulbenkian Ciência (IGC) in collaboration with IHMT won the Pfizer Award 2015 in the field of ​​basic research. In the study, published in the scientific journal Cell, the researchers found that specific components of bacteria in the gut can induce the production of natural antibodies against Plasmodium, the parasite that causes malaria, providing protection against this disease.

The investigation is led by Miguel Soares of the IGC, and has the support of Henrique Silveira, deputy director of IHMT and scientific coordinator of the R&D center GHTM.

The Pfizer Awards are a partnership between the Society of Medical Sciences of Lisbon and the biopharmaceutical Pfizer.

According to the World Health Organization, 214 million cases of malaria were reported in 2015. “The mortality associated with malaria declined by 20-25% in the last decade, presumably due to the introduction of global control programs, such as the distribution of mosquito nets and effective drugs against Plasmodium. However, the inherent ability of the parasite to become refractory to antimalarial drugs continues to seriously compromise the eradication of this disease, stressing the need to develop an effective vaccine”, says Miguel Soares.

See the study Gut microbiota elicits the Protective Immune Response against Malaria Transmission

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Pinterest (Opens in new window) Pinterest
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Funding

UID/04413/2025 - DOI: 10.54499/UID/04413/2025

UID/PRR/04413/2025 - DOI: 10.54499/UID/PRR/04413/2025

UID/PRR2/04413/2025 - DOI: 10.54499/UID/PRR2/04413/2025

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2026 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

Loading Comments...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.